# News

## Evidation Insights from 165,000 People Show Continued Growth Potential Amid Uneven Adoption in the GLP-1 Market
Among 119,000 surveyed individuals actively trying to lose weight, 24% had ever used prescription medication for weight management and 15% had ever used a GLP-1, suggesting significant room for continued market growth as adoption varies by age, gender, and income.

## Evidation Launches Interactive Dermatology Cohort; Shares Preliminary Real-World Insights
New cohort is designed to address gaps in understanding treatment journeys across the full continuum of care. Insights show that consumer health products play a critical part in how individuals understand and manage their skin conditions.

## Evidation partners with 1upHealth to integrate diverse sources of permissioned real-world health data for research
Evidation and 1upHealth announce a long-term partnership to advance patient-centered, real-world health research.

## Evidation Launches Temporal Proteomics Platform to Power Autoimmune Research
New AI-enabled data collection platform will drive the development of novel multimodal datasets for biomarker discovery, treatment-response modeling, and foundation models of the immune system.

## Evidation Shares Insights on Real-World GLP-1 Dosing Behaviors from Over 60,000 Individuals
New insights from Evidation’s cardiometabolic health and weight management cohort, comprised of over 160,000 individuals, show what factors shape real-world dosing decisions.

## Evidation Appoints Dr. Ghazanfar Khan as Chief Medical Officer
Evidation appoints Dr. Ghazanfar Khan as Chief Medical Officer. Dr. Khan will advance Evidation’s leadership in real-world data by driving the clinical strategy for direct-to-participant multimodal data collection to fuel AI-powered discovery and evidence generation.

## Evidation Appoints Leslie Oley Wilberforce as CEO
Evidation appoints Leslie Oley Wilberforce as CEO. Wilberforce will lead Evidation’s next phase of growth in interactive real-world data and health research.

## Evidation appoints Phil Johnson as Chief Commercial Officer
Evidation announces the addition of a new Chief Commercial Officer, Phil Johnson, and board member, Ian Lennox.

## Trialbee and Evidation partner to accelerate and diversify clinical research recruitment
Learn how Evidation and Trialbee's joint offering and shared commitment to inclusion and data transparency drives enrollment outcomes.

## Rock Health shares findings from weight care survey with Evidation
Evidation helped Rock Health conduct surveys that investigated experience and perceptions of a variety of weight care solutions. Read key highlights here.